Citation, commencement and interpretation

1.-(1) This Order may be cited as the Prescription Only Medicines (Human Use) Amendment Order 1999 and shall come into force on 22nd April 1999.

(2) In this Order, "the principal Order" means the Prescription Only Medicines (Human Use) Order 1997(4).

Amendment of Schedule 1 to the principal Order

2. In Schedule 1 to the principal Order (which specifies substances which if included in medicinal products make those products prescription only medicines and exemptions from restrictions on the sale and supply of prescription only medicines)-

(a)in relation to the substance Aspirin(5), the entries in columns 2, 3 and 5 numbered "(1)" are re-numbered "(2)", the entry in column 3 numbered "(2)" is re-numbered "(3)"; and, before those entries re-numbered "(2)", there are inserted the following entries-

• in column 2-

  "(1) 75mg",

• in column 3-

  "(1) Non-effervescent tablets and capsules",

• in column 5-

  "(1) The quantity sold or supplied in one container or package shall not exceed 100

  • The quantity of non-effervescent tablets, capsules or a combination of both sold or supplied to a person at any one time shall not exceed 100";

(b)in relation to the substance Beclomethasone Dipropionate(6), in the entry in column 5, for "5,600 mcg" there is substituted "20,000 mcg";

(c)in relation to the substance Hydrocortisone(7), the entry in each of columns 2 and 5 is, and the entries in column 3 are, numbered "(2)"; and, before the entries in columns 2, 3 and 5, there are inserted the following entries-

• in column 2-

  "(1) 0.5 per cent",

• in column 3-

  "(1) External

  • For use in combination with Nystatin of maximum strength 3.0 per cent for intertrigo

  • For use in adults and children not less than 10 years",

• in column 5-

  "(1) Container or package containing not more than 15g of medicinal product";

(d)in relation to the substance Nystatin, there are inserted the following entries-

• in column 2-

  • "3.0 per cent",

• in column 3-

  "External

  For use in combination with Hydrocortisone of maximum strength 0.5 per cent for intertrigo

  For use in adults and children not less than 10 years",

• in column 5-

  "Container or package containing not more than 15g of medicinal product"; and

(e)there is inserted in column 1, at the appropriate place in the alphabetical order of the entries in that column, each of the following substances-

"Candesartan Cilexetil"

"Lornoxicam"

"Losartan Potassium"

"Nebivolol Hydrochloride"

"Nisoldipine"

"Propiverine Hydrochloride"

"Quetiapine Fumarate"

"Tacalcitol Monohydrate".

Explanatory Note

(This note is not part of the Order)

This Order amends the Prescription Only Medicines (Human Use) Order 1997 ("the principal Order") which specifies descriptions and classes of prescription only medicines (i.e. medicinal products which, subject to exemptions, may be sold or supplied by retail only with a prescription given by an appropriate practitioner and which may be administered only by or in accordance with the directions of such a practitioner). Under the principal Order, products are included in a class of medicines by reason of the substances contained in them, subject to their being excluded in specified circumstances.

The amendments made by this Order are as follows-

• Amendments to the conditions under which Aspirin may be sold or supplied otherwise than as a prescription only medicine (to permit containers or packages holding up to 100 tablets or capsules of non-effervescent Aspirin, at 75 mg strength, to be so sold or supplied), and the insertion of conditions under which Hydrocortisone in combination with Nystatin may be so sold or supplied (for the treatment of intertrigo).

• Amendment to the conditions under which Beclomethasone Dipropionate may be sold or supplied otherwise than as a prescription only medicine, correcting an error in the principal Order;

• The inclusion in Schedule 1 to the principal Order of the substances Candesartan Cilexetil, Lornoxicam, Losartan Potassium, Nebivolol Hydrochloride, Nisoldipine, Propiverine Hydrochloride, Quetiapine Fumarate and Tacalcitol Monohydrate.

An assessment of the cost to business of complying with this Order has been made, copies of which have been placed in the libraries of both Houses of Parliament. Further copies may be obtained from the Department of Health, Medicines Control Agency, Information Centre, Room 1207 Market Towers, 1 Nine Elms Lane, London SW8 5NQ.